{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:42:17Z","timestamp":1788903737390,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clinre.2025.102646","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:43:20Z","timestamp":1751564600000},"page":"102646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The impact of low HER2 expression on clinicopathological features and clinical outcomes in patients with metastatic gastric cancer"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2981-8098","authenticated-orcid":false,"given":"Murad","family":"Guliyev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamkhal","family":"Safarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"G\u00fcnalt\u0131l\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Cem","family":"Fidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"\u00c7erme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclin","family":"Alkan \u015een","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Emin \u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuray","family":"Kepil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zkan","family":"Alan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebi Serkan","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2025.102646_bib0001","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.clinre.2025.102646_bib0002","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Annal. Oncol"},{"key":"10.1016\/j.clinre.2025.102646_bib0003","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.clinre.2025.102646_bib0004","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.clinre.2025.102646_bib0005","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-line Nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.clinre.2025.102646_bib0006","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"The Lancet"},{"key":"10.1016\/j.clinre.2025.102646_bib0007","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric. Cancer"},{"key":"10.1016\/j.clinre.2025.102646_bib0008","first-page":"2419","volume":"382","author":"Shitara","year":"2020"},{"key":"10.1016\/j.clinre.2025.102646_bib0009","doi-asserted-by":"crossref","first-page":"S869","DOI":"10.1016\/j.annonc.2023.09.1463","article-title":"1551P Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer","volume":"34","author":"Lee","year":"2023","journal-title":"Annal. Oncol"},{"key":"10.1016\/j.clinre.2025.102646_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103679","article-title":"HER2-low gastric cancer: is the subgroup targetable?","volume":"9","author":"Shimozaki","year":"2024","journal-title":"ESMo Open."},{"key":"10.1016\/j.clinre.2025.102646_bib0011","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.22.00575","article-title":"Trastuzumab deruxtecan in anti\u2013Human epidermal growth factor receptor 2 treatment\u2013Naive patients with Human epidermal growth factor receptor 2\u2013Low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial","volume":"41","author":"Yamaguchi","year":"2023","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.clinre.2025.102646_bib0012","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s10120-021-01168-7","article-title":"Phase I study of the recombinant humanized anti-HER2 monoclonal antibody\u2013MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors","volume":"24","author":"Xu","year":"2021","journal-title":"Gastric. Cancer"},{"key":"10.1016\/j.clinre.2025.102646_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101582","article-title":"Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric\/gastroesophageal junction adenocarcinoma","volume":"8","author":"Nakayama","year":"2023","journal-title":"ESMo Open."},{"key":"10.1016\/j.clinre.2025.102646_bib0014","first-page":"1","article-title":"Impact of HER2-low status in metastatic gastric cancer: A real-world retrospective cohort study","author":"Unal","year":"2024","journal-title":"Oncology."},{"key":"10.1016\/j.clinre.2025.102646_bib0015","article-title":"Clinicopathological and prognostic significance of HER2-low expression in advanced gastric cancer: a retrospective observational study","author":"Narita","year":"2024","journal-title":"Oncologist."},{"key":"10.1016\/j.clinre.2025.102646_bib0016","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ajcp\/aqw206","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma guideline from the College of American Pathologists, American Society for clinical Pathology, and American Society of Clinical Oncology","volume":"146","author":"Bartley","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.clinre.2025.102646_bib0017","doi-asserted-by":"crossref","first-page":"S869","DOI":"10.1016\/j.annonc.2023.09.1463","article-title":"1551P Clinicopathologic characteristics and genomic profiling of HER2-low advanced gastric cancer","volume":"34","author":"Lee","year":"2023","journal-title":"Annal. Oncol"},{"key":"10.1016\/j.clinre.2025.102646_bib0018","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.4_suppl.287","article-title":"Comparative analysis of the molecular profile and tumor immune microenvironment (TIME) of human epidermal growth factor receptor 2 (HER2) low (L)- versus high (H)-expressing gastroesophageal cancers (GEC)","author":"Alqahtani","year":"2023","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.clinre.2025.102646_bib0019","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.3748\/wjg.v19.i14.2171","article-title":"Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer","volume":"19","author":"He","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.clinre.2025.102646_bib0020","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1093\/annonc\/mdn169","article-title":"HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target","volume":"19","author":"Gravalos","year":"2008","journal-title":"Annal. Oncol"},{"key":"10.1016\/j.clinre.2025.102646_bib0021","first-page":"75","article-title":"Incidence of gastric and gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity","author":"Kang","year":"2008","journal-title":"Gastrointestinal Cancers Symposium"},{"key":"10.1016\/j.clinre.2025.102646_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101624","article-title":"Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer","volume":"29","author":"Yu","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.clinre.2025.102646_bib0023","doi-asserted-by":"crossref","first-page":"S899","DOI":"10.1016\/j.annonc.2020.08.1928","article-title":"1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study","volume":"31","author":"Yamaguchi","year":"2020","journal-title":"Annal. Oncol"},{"key":"10.1016\/j.clinre.2025.102646_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS424","article-title":"Phase 1b\/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03)","author":"Janjigian","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clinre.2025.102646_bib0025","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3390\/cancers16091747","article-title":"Recent progress in treatment for HER2-positive advanced gastric cancer","volume":"16","author":"Kawakami","year":"2024","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.clinre.2025.102646_bib0026","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-015-3503-3","article-title":"A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity","volume":"153","author":"Yao","year":"2015","journal-title":"Breast. Cancer Res. Treat."}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125001238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125001238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T15:12:58Z","timestamp":1754320378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125001238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2210740125001238"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102646","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of low HER2 expression on clinicopathological features and clinical outcomes in patients with metastatic gastric cancer","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102646"}}